
ResMed RMD
$ 256.15
-0.57%
Annual report 2022
added 08-12-2022
ResMed Deferred Revenue 2011-2026 | RMD
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue ResMed
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 109 M | 110 M | 98.6 M | 88.7 M | 60.8 M | 51.9 M | 50 M | 36.1 M | 42.4 M | 45 M | 41.6 M | 45.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 M | 36.1 M | 64.9 M |
Quarterly Deferred Revenue ResMed
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 112 M | 112 M | 113 M | 110 M | 110 M | 105 M | 102 M | 98.6 M | 98.6 M | 93 M | 87 M | 88.7 M | 88.7 M | 72.7 M | 64.8 M | 60.8 M | 58 M | 53.3 M | 53.3 M | 51.9 M | 51.9 M | 46.4 M | 47.7 M | 50 M | 50 M | 36.1 M | 34.8 M | 36.1 M | 36.1 M | 36.9 M | 39.5 M | 42.4 M | 42.4 M | 42.6 M | 43.9 M | 45 M | 45 M | 43.8 M | 43 M | 41.6 M | 41.6 M | 41.8 M | 41.9 M | 45.1 M | 45.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | 34.8 M | 62.3 M |
Deferred Revenue of other stocks in the Medical instruments industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Baxter International
BAX
|
131 M | $ 20.1 | 1.85 % | $ 10.3 B | ||
|
Luminex Corporation
LMNX
|
21.1 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
59.8 K | - | -9.52 % | $ 20.6 M | ||
|
ICU Medical
ICUI
|
30.4 M | $ 148.85 | -0.79 % | $ 3.63 B | ||
|
Antares Pharma, Inc.
ATRS
|
3.94 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
26.2 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
26.8 K | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
110 M | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
782 M | - | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
1.96 M | $ 8.57 | 2.15 % | $ 173 M | ||
|
Alcon
ALC
|
581 M | $ 81.03 | -0.12 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
125 K | $ 5.39 | -1.1 % | $ 246 M | ||
|
Haemonetics Corporation
HAE
|
43.3 M | $ 66.55 | 0.88 % | $ 3.35 B | ||
|
AngioDynamics
ANGO
|
200 K | $ 10.3 | 3.21 % | $ 421 M | ||
|
OraSure Technologies
OSUR
|
3 M | $ 2.78 | -0.54 % | $ 207 M | ||
|
The Cooper Companies
COO
|
128 M | $ 81.34 | 1.21 % | $ 16.2 B | ||
|
Masimo Corporation
MASI
|
95.5 M | $ 137.49 | 0.91 % | $ 7.33 B | ||
|
Harvard Bioscience
HBIO
|
4.51 M | $ 0.5 | -6.73 % | $ 21.2 M | ||
|
Merit Medical Systems
MMSI
|
572 K | $ 80.93 | 0.85 % | $ 4.71 B | ||
|
iRhythm Technologies
IRTC
|
2.93 M | $ 154.21 | 3.5 % | $ 4.81 B | ||
|
LeMaitre Vascular
LMAT
|
552 K | $ 84.97 | 1.32 % | $ 1.91 B | ||
|
STERIS plc
STE
|
160 M | $ 261.9 | 0.02 % | $ 25.8 B | ||
|
Intuitive Surgical
ISRG
|
469 M | $ 505.17 | -0.47 % | $ 179 B | ||
|
NeuroMetrix
NURO
|
1.96 M | - | 5.05 % | $ 9.02 M | ||
|
Microbot Medical
MBOT
|
16.8 K | $ 1.81 | -2.96 % | $ 18.5 M | ||
|
Nephros
NEPH
|
70 K | $ 4.35 | -0.91 % | $ 45.2 M | ||
|
Milestone Scientific
MLSS
|
340 K | $ 0.29 | -2.67 % | $ 23.1 M | ||
|
Envista Holdings Corporation
NVST
|
146 M | $ 23.4 | 0.13 % | $ 4.03 B | ||
|
Pro-Dex
PDEX
|
202 K | $ 38.77 | -1.61 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
305 K | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
16 K | $ 13.76 | 0.99 % | $ 661 M | ||
|
Repligen Corporation
RGEN
|
17.1 M | $ 150.44 | -3.8 % | $ 8.38 M | ||
|
BioLife Solutions
BLFS
|
103 K | $ 21.91 | -2.97 % | $ 1.01 B | ||
|
Stereotaxis
STXS
|
6.66 M | $ 2.21 | -5.36 % | $ 178 M | ||
|
Retractable Technologies
RVP
|
377 K | $ 0.7 | -1.03 % | $ 21 M | ||
|
STAAR Surgical Company
STAA
|
3.75 M | $ 18.9 | -0.24 % | $ 928 M | ||
|
West Pharmaceutical Services
WST
|
49.6 M | $ 231.57 | -0.4 % | $ 16.9 B | ||
|
DENTSPLY SIRONA
XRAY
|
95 M | $ 12.47 | 1.63 % | $ 2.53 B |